...
机译:用不同的易用紫外线和IT-Fusion Valiants对高级和ITALL和IT-Reallanged非小细胞肺癌的次曲调
Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Pathol Beijing Peoples R China;
Chinese Acad Med Sci Canc Hosp Dept Med Oncol Shenzhen Peoples R China;
Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Pathol Beijing Peoples R China;
Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Pathol Beijing Peoples R China;
Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Pathol Beijing Peoples R China;
Peking Union Med Coll Beijing Peoples R China;
Burning Rock Biotech Guangzhou Guangdong Peoples R China;
Burning Rock Biotech Guangzhou Guangdong Peoples R China;
Peking Union Med Coll Beijing Peoples R China;
Chinese Acad Med Sci Canc Hosp Natl Canc Ctr Dept Pathol Beijing Peoples R China;
ALK translocation; Non-small cell lung cancer; Crizotinib; Next-generation sequencing; Variants;
机译:用不同的易用紫外线和IT-Fusion Valiants对高级和ITALL和IT-Reallanged非小细胞肺癌的次曲调
机译:ALK融合变体检测通过靶向RNA-NEXT GENAY测序和临床反应在ALK阳性非小细胞肺癌中对CRIZOTINIB进行临床反应
机译:一个主题的变体:克唑替尼应答在ALK阳性非小细胞肺癌中的生物标记?
机译:PET / CT多模态融合图像的放射性标记生物标志物用于预测晚期非小细胞肺癌患者的免疫治疗反应
机译:导致晚期非小细胞肺癌患者营养风险的症状:在晚期肺癌人群中进行营养筛查的重要性
机译:临床因素,ALK融合变异和BIM多态性对克唑替尼治疗的晚期EML4–ALK重排非小细胞肺癌的影响
机译:Croizotinib与铂金疗法为具有不同ROS1融合变体的先进非小细胞肺癌的一线治疗